NeuroSense Announces Year End 2022 Financial Results and Provides Business UpdatePRNewsWire • 03/22/23
NEUROSENSE THERAPEUTICS LTD. TO PARTICIPATE IN RENMARK'S VIRTUAL NON-DEAL ROADSHOW SERIES ON, TUESDAY, MARCH 21 AND TUESDAY, MARCH 28, 2023PRNewsWire • 03/14/23
NeuroSense and QuantalX Collaborate to Improve Early Detection and Treatment of Neurodegenerative DiseasesPRNewsWire • 02/09/23
NeuroSense Receives Approval in Germany to Enroll Patients in its Phase 2b ALS TrialPRNewsWire • 02/08/23
NeuroSense Expands its Phase 2b ALS PARADIGM Trial to Canada and Withdraws Protocol from U.S. IND to Align its Clinical Strategy with the FDA for a Potential Pivotal Phase 3 StudyPRNewsWire • 02/06/23
NeuroSense Therapeutics Reports Positive Final Results from Alzheimer's Biomarker StudyPRNewsWire • 01/19/23
NeuroSense Announces Third Quarter 2022 Financial Results and Provides Business UpdatePRNewsWire • 12/01/22
NeuroSense Receives Regulatory Approval to Commence Patient Enrollment in Italy for its Phase 2b Trial in ALSPRNewsWire • 11/16/22
NeuroSense Therapeutics to Participate in BIO-Europe Partnering Conference on October 24-26, 2022 in Lepzing, GermanyPRNewsWire • 10/21/22
NeuroSense Therapeutics Provides CEO's Q3 Update and Nasdaq Opening Bell Ceremony Remarks VideoPRNewsWire • 10/18/22
NeuroSense Therapeutics to Ring Nasdaq Opening Bell and Host The ALS Combination Therapy Summit on October 13, 2022 in New York CityPRNewsWire • 10/12/22
NeuroSense Announces Positive PrimeC Pharmacokinetic Study Results & Anticipates Phase IIb ALS Enrollment to Expand into the USPRNewsWire • 09/28/22
NeuroSense Announces Positive PrimeC Toxicology Data Supportive of Current Phase IIb PARADIGM ALS Clinical TrialPRNewsWire • 09/20/22
NeuroSense Announces Peer-Reviewed Publication of PrimeC Phase IIa ALS Study in Amyotrophic Lateral Sclerosis and Frontotemporal DegenerationPRNewsWire • 09/19/22
NeuroSense Announces Second Quarter 2022 Financial Results and Provides Business UpdatePRNewsWire • 08/31/22
NeuroSense Joins EverythingALS Open Innovation Consortium; Set to Enroll US and EU Patients in Phase IIb StudyPRNewsWire • 08/02/22